Charles W. Newton - Aug 11, 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Financial Officer
Signature
/s/ Allison Peth, Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Aug 11, 2025
Transactions value $
-$2,785
Form type
4
Date filed
8/13/2025, 09:06 PM
Previous filing
Jun 13, 2025
Next filing
Aug 22, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Newton Charles W. Chief Financial Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO /s/ Allison Peth, Attorney-in-Fact 2025-08-13 0001866219

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Sale -$1.38K -131 -1.45% $10.53 8.9K Aug 11, 2025 Direct F1, F2, F3, F4
transaction LYEL Common Stock Sale -$1.41K -136 -1.53% $10.34 8.76K Aug 12, 2025 Direct F5, F6, F7
holding LYEL Common Stock 10K Aug 11, 2025 Co-grantor and Co-trustee F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F2 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Fonn 4.
F3 Includes 390 shares acquired on May 18, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
F4 On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F5 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F6 The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F7 On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F8 Shares held by The Charles & Lisa Newton Living Trust. The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust.